ACTUATE THERAPEUTICS, INC. · NASDAQ Global · priced Aug 13, 2024 · $22M raised · Under $50M
Price since listing
- Hype
- Distribution
- Lock-up window
- Valley
- Accumulation
- Recovery
Volume bars are coloured by lifecycle phase. Markers: lock-up and early release (orange), earnings releases (E), follow-on offerings (F), research signals (rule id and signal; arrow up = buy signal, arrow down = sell or short signal, or sell signal for deals under $50M). Current phase: Valley.
Performance since the IPO
- ACTU
- S&P 500 (SPY)
- Typical IPO under $50m
- Middle 50% of those IPOs
ACTU measured from its offer price; S&P 500 from the first trading day. The typical-IPO line is the median of 382 under $50m IPOs from 2014–2025, by trading day.
Company
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric…
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Employees
- 12
- Market cap
- $9M
- Website
- actuatetherapeutics.com
From the prospectus
- Lock-up
- 180 days
- Early release on earnings
- No
- Price-based early release
- No
- Staggered release
- No
- Float sold in IPO
- 15%
- Locked shares per share sold
- 5.8×
- Backed by
- Venture capital
- Lead underwriters
- Titan Partners Group LLC, a division of American Capital Partners, LLC, Newbridge Securities Corporation
- Dual-class shares
- No
- Controlled company
- No
- Foreign private issuer
- No
Extracted from the final prospectus on SEC EDGAR.
Returns vs offer, compared with 189 IPOs under $50m
| Horizon | ACTU | Peer median | Peers below offer |
|---|---|---|---|
| Day 1 | +7.6% | 0.0% | 47% n=189 |
| Day 20 | +2.5% | -10.3% | 61% n=187 |
| Day 60 | +10.0% | -34.4% | 70% n=184 |
| Day 120 | +15.8% | -51.8% | 78% n=177 |
| Day 180 | +18.8% | -68.7% | 83% n=174 |
Research signals
- BuyRule C1: buy signal for 40 sessionsFeb 5, 2026 · CapitulationPast signals (357, deals under $50M): rose 42% · median -6.8% · dropped 25%+ during the hold 49%backtest
Buy signals passed on returns relative to IPOs of the same year, size and age, most of which fall after listing. A buy signal can beat its peers and still lose money.
- BuyRule RL: buy signal for 60 sessionsJan 10, 2025 · Pre-unlock risk tierPast signals (59, deals under $50M): rose 49% · median 0.0% · dropped 25%+ during the hold 27%backtest
Buy signals passed on returns relative to IPOs of the same year, size and age, most of which fall after listing. A buy signal can beat its peers and still lose money.
- SellRule F1: sell signal for 100 sessionsSep 10, 2024 · Microcap dealPast signals (387, deals under $50M): fell 73% · median -29.0% · rallied 25%+ during the hold 50%backtest
Deal under $50M: published as a sell signal only, because shorting such shares is usually impractical (hard to borrow, high borrow fees, frequent squeezes).
Rules frozen as v1; signals dated from Oct 29, 2026 are live, earlier ones show what the frozen rules would have flagged. See methodology.
The rules run independently, so one IPO can carry buy and sell signals at the same time; each label reports only its own rule's history.
Past figures cover all 4,312 signals the published frozen v1 rules produce on 2014–2025 IPOs, close to close over each signal's holding period. Returns start at the close of the signal session; signals are published after that close, so the first price available to a reader is the next session's. Only 1,192 of 2,368 operating-company IPOs from those years have usable Yahoo Finance price data; most of the rest no longer trade under their IPO ticker (delisted, acquired or renamed), so the figures probably understate declines. These are hypothetical results, not trades: the rules were selected on these same years with the benefit of hindsight, so the figures likely overstate what live signals will do. The live track record is the real test. Trading costs and borrow fees are not included. Past results do not predict future results.
Research signals only, not investment advice. Lock-up terms come from prospectuses; prices from Yahoo Finance and may be delayed or wrong.